Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?
نویسندگان
چکیده
Original Research Arrhythmia and Electrophysiology Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Sean D. Pokorney, Jonathan P. Piccini, Susanna R. Stevens, Manesh R. Patel, Karen S. Pieper, Jonathan L. Halperin, Günter Breithardt, Daniel E. Singer, Graeme J. Hankey, Werner Hacke, Richard C. Becker, Scott D. Berkowitz, Christopher C. Nessel, Kenneth W. Mahaffey, Keith A. A. Fox, Robert M. Califf, and for the ROCKET AF Steering Committee & Investigators e002197 doi: 10.1161/JAHA.115.002197
منابع مشابه
Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
BACKGROUND Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate combined risk prediction model. METHODS AND RESULTS Clinical, genetic, and outcomes data were use...
متن کاملIndividualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study
In patients with stable coronary artery disease (CAD) without overt heart failure, ACE inhibitors are among the most commonly used drugs as these agents have been proven effective in reducing the risk of cardiovascular events. Considerable individual variations in the blood pressure response to ACE inhibitors are observed and as such heterogeneity in clinical treatment effect would be likely as...
متن کاملCost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
BACKGROUND The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported. OBJECTIVE To assess the cost effectiveness of perindopril in stable coronary heart disease in the UK. METHODS Clinical and resource use data were taken from the EUROPA trial. Costs included drugs and hospitalisations. Health-related quality of...
متن کاملGenetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
AIMS The efficacy of angiotensin-converting enzyme (ACE)-inhibitors in stable coronary artery disease (CAD) may be increased by targeting the therapy to those patients most likely to benefit. However, these patients cannot be identified by clinical characteristics. We developed a genetic profile to predict the treatment benefit of ACE-inhibitors exist and to optimize therapy with ACE-inhibitors...
متن کاملDiagnosis of Coronary Artery Disease via a Novel Fuzzy Expert System Optimized by Cuckoo Search
In this paper, we propose a novel fuzzy expert system for detection of Coronary Artery Disease, using cuckoo search algorithm. This system includes three phases: firstly, at the stage of fuzzy system design, a decision tree is used to extract if-then rules which provide the crisp rules required for Coronary Artery Disease detection. Secondly, the fuzzy system is formed by setting the intervals ...
متن کامل